In clinical studies in which TYMLOS was administered once daily to postmenopausal women with osteoporosis: Early increases in a bone formation marker peaked at month 11
P1NP* bone formation marker levels were maintained above baseline throughout treatment1
Bone turnover marker levels at peak and at end of study with TYMLOS1
Serum procollagen type 1 N-propeptide.1
Serum collagen type 1 cross-linked C-telopeptide.1
See the abaloparatidemechanism of action video
Reference: 1. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2017.